Clinical trial

Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected…

NCT00089466 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed

Key facts

NCT number NCT00089466
Title Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients
Official title Phase IB/IIA Dose-Finding Safety and Activity Study of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor) in HIV-Infected Subjects
Lead sponsor National Institute of Allergy and Infectious Diseases (NIAID), NIH
Collaborators Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Status Completed
Phase Phase 1/Phase 2
Study type Interventional
Conditions HIV Infections
Intervention type Drug
Interventions AMD11070
Enrollment 6
Start date Nov 1, 2004
Primary completion Jun 1, 2006
Completion Jan 1, 2009
First posted Aug 6, 2004
Last update posted Nov 9, 2021
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies